S.T. Stent is a Misgav, Israel-based developer of a removable nasal stent intended for implantation following sinus surgery. The stent is designed to keep the sinus cavity open for up to 28 days, allowing sinus tissue to heal. Removal of the stent requires a simple in‑office procedure performed without anesthesia. The company sees additional markets in nose job failures, chronic allergic rhinitis, and as a direct stenting alternative to replace sinuplasty. S.T. Stent completed a $450K funding round to enable device evaluation in humans with significant statistics and to pursue regulatory approval. The company is led by CEO Joseph Flomenbilt, Ph.D., and is a portfolio company of Trendlines Medical.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2015